HER2-targeted therapy.
CDK4/6 inhibitors.
mTOR inhibitors.
PIK3CA inhibitors.
Chemotherapy.
Immunotherapy.
Surgery for patients with limited symptomatic metastases.
Radiation therapy for patients with limited symptomatic metastases.
Bone-modifying therapy for patients with bone metastases.
In many cases, these therapies are given in sequence and used in various combinations.
Cytological or histological documentation of metastatic disease, with testing of ER, progesterone receptor, and HER2 statuses, should be obtained at the time of metastatic presentation, if possible.
If not possible, it is appropriate to consider liquid biopsy (via circulating tumor cell and/or circulating tumor DNA testing).